MOTS-C and Liver Research: Mitochondrial Peptide Biology, Hepatic Metabolism and NAFLD Mechanisms UK 2026

This article is intended for researchers and laboratory professionals. All peptides discussed are for research use only (RUO) and are not approved for human administration, therapeutic use, or clinical application. PeptidesLab UK supplies research-grade MOTS-C for in vitro and in vivo laboratory investigations only.

MOTS-C Biology: Mitochondrial-Derived Peptide and Hepatic Metabolic Regulation

MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA-c, 16 amino acids: MRWQEMGYIFYPRKLR, MW 2174 Da) is a mitochondrial-derived peptide (MDP) encoded within the 12S ribosomal RNA gene of mitochondrial DNA (mtDNA). Unlike nuclear-encoded peptides, MOTS-C arises from a short open reading frame within the mitochondrial 12S rRNA, making it one of a growing family of mitogenically-encoded peptides (alongside humanin and the SHLP family) that participate in inter-organelle and inter-cellular metabolic communication. MOTS-C is processed within mitochondria and secreted into the cytoplasm and subsequently into the circulation, functioning as a metabolic hormone with peak circulating concentrations in young healthy adults of ~100-200 pM detected by LC-MS/MS or sandwich ELISA.

The liver is the primary metabolic organ where MOTS-C exerts its most well-characterised effects. Research demonstrates that MOTS-C activates AMPK (AMP-activated protein kinase, the cellular energy sensor) in hepatocytes through a folate cycle-AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) dependent mechanism: MOTS-C disrupts the methionine cycle and folate metabolism, increasing AICAR accumulation, which then allosterically activates AMPK (Thr-172 phosphorylation). This MOTS-C → folate cycle → AICAR → AMPK pathway represents a mechanistically distinct route to AMPK activation compared to the canonical energy-sensing AMP:ATP ratio mechanism, creating pharmacological tractability for uncoupling MOTS-C effects from general cellular energy depletion.

AMPK Activation and Hepatic Glucose Metabolism Research

AMPK Thr-172 phosphorylation in response to MOTS-C (1-10 μM, 30-120 min) is the primary molecular readout in hepatocyte research, quantified by western blot (anti-pAMPK Thr-172, Cell Signaling 2535; anti-total AMPK, Cell Signaling 2532, ratio normalised to total protein by Ponceau S). Downstream AMPK substrate phosphorylation: ACC1 Ser-79 (fatty acid synthesis inhibition, Cell Signaling 3661); RAPTOR Ser-792 (mTORC1 inhibition, Cell Signaling 2083); ULK1 Ser-555 (autophagy activation, Cell Signaling 5869); and SIRT1 activation (AMPK-SIRT1 axis via increased NAD+ generation). AICAR mechanism specificity confirmed by: (i) AICAR pathway blockade using AICA riboside transport inhibitor dipyridamole (10 μM) or AMPK-dead HepG2 cells (dominant-negative AMPK α1 D157A/D139A mutation); (ii) folate cycle perturbation confirmed by increased SAH:SAM ratio (S-adenosylhomocysteine:S-adenosylmethionine, measured by LC-MS/MS) in MOTS-C-treated hepatocytes; (iii) methotrexate (MTX, dihydrofolate reductase inhibitor, 1 μM) phenocopy of MOTS-C AMPK activation confirms folate cycle dependence.

Hepatic gluconeogenesis suppression is the primary metabolic endpoint: PEPCK1 (PCK1) and G6Pase (G6PC) mRNA by qPCR (Taqman), PEPCK1 protein western, and FoxO1 Ser-256 nuclear exclusion (AMPK → Akt-FoxO1 axis, confocal IF or nuclear/cytoplasmic fractionation western). Pyruvate tolerance test (PTT) in vivo (2g/kg sodium pyruvate i.p., 18h fasted C57BL/6, blood glucose 0-120 min glucometer) with MOTS-C (5 mg/kg i.p., 30 min before PTT) measures acute hepatic gluconeogenesis inhibition. Glycogen synthesis: GS Ser-641 dephosphorylation (activation) by AMPK-GSK-3β Ser-9, PAS staining and enzymatic glycogen quantification (amyloglucosidase hydrolysis, glucose oxidase colorimetric) in livers from MOTS-C-treated mice.

NAFLD Research: Lipid Accumulation, de Novo Lipogenesis, and Steatosis

NAFLD is the leading hepatic manifestation of metabolic syndrome, and MOTS-C’s AMPK-activating properties position it as a mechanistic research tool in NAFLD biology. AMPK activation in hepatocytes directly suppresses de novo lipogenesis (DNL) through ACC1 Ser-79 phosphorylation (reducing malonyl-CoA, substrate for FAS), SREBP-1c transcriptional suppression (nuclear SREBP-1c p68:total SREBP-1c p125 ratio western), and mTORC1 inhibition (reducing SREBP-1c processing). In parallel, AMPK activates fatty acid oxidation (FAO) via CPT-1α derepression (malonyl-CoA inhibition lifted), PGC-1α Ser-570 dephosphorylation, and ULK1-mediated mitophagy (removing dysfunctional mitochondria limiting FAO capacity).

In vitro NAFLD model: HepG2 or AML12 hepatocytes, palmitate 0.5 mM + oleate 1 mM (BSA-complexed 5:1 molar, 24-48h) producing steatosis confirmed by Oil Red O (isopropanol elution OD510) and BODIPY 493/503 neutral lipid staining (flow cytometry, geometric mean fluorescence). MOTS-C (1-10 μM) co-treatment assessment: (i) Oil Red O and BODIPY reduction (% versus vehicle); (ii) [¹⁴C]-acetate DNL assay (4h pulse, Folch extraction, scintillation counting of lipid-associated ¹⁴C, nmol acetate/mg protein/h); (iii) ³H-palmitate FAO assay (4h, aqueous ³H₂O release as FAO product, nmol palmitate oxidised/mg protein/h); (iv) lipid profiling by LC-MS/MS (QTOF or triple-quadrupole lipidomics): TG, DAG, ceramide species, LPC identifying specific lipotoxic species reduced by MOTS-C. Compound C (dorsomorphin, 10 μM, AMPK inhibitor) confirms AMPK-dependence; AMPK α1α2 double KO hepatocytes (generated by Ad-Cre deletion in Ampkα1fl/fl×Ampkα2fl/fl primary hepatocytes) provide genetic AMPK loss-of-function validation.

In vivo NAFLD models: (i) HFD (60% kcal fat, Research Diets D12492, 16-24 week C57BL/6) with MOTS-C 5 mg/kg/day s.c. or i.p. from week 8 (treatment) or week 0 (prevention); (ii) AMLN diet (Research Diets D09100301, with trans-fat + fructose + cholesterol, 16-week) producing NASH with fibrosis. Primary endpoints: liver TG content (Folch chloroform:methanol 2:1 extraction, GPO-PAP enzymatic assay); NAS score (steatosis 0-3 + lobular inflammation 0-3 + ballooning 0-2, H&E); Sirius Red % area and Metavir fibrosis stage; plasma ALT/AST (IDEXX Catalyst). Metabolic phenotyping: EchoMRI (fat mass, lean mass, fluid), GTT (2g/kg glucose i.p., AUC), ITT (0.75 IU/kg insulin i.p., glucose nadir), HOMA-IR (fasting glucose × fasting insulin/22.5).

Mitochondrial Function Research: Biogenesis, Respiration, and ROS

MOTS-C’s mitochondrial origin gives it unique mechanistic relevance to hepatic mitochondrial biology. Seahorse XFe96 extracellular flux analysis in MOTS-C-treated HepG2 or primary hepatocytes: OCR (oxygen consumption rate) — basal, ATP-linked (oligomycin 1 μM), maximal (FCCP 0.5-1 μM uncoupling), proton leak, and non-mitochondrial. ECAR (extracellular acidification rate) — glycolytic rate. Spare respiratory capacity (SRC = maximal OCR − basal OCR) reflects mitochondrial flexibility and is impaired in NAFLD; MOTS-C treatment restores SRC through AMPK-PGC-1α-ERRα-mtTFA transcriptional axis. PGC-1α Ser-570 phosphorylation western (active dephosphorylated form vs AMPK-phosphorylated inactive Ser-570) with confocal PGC-1α nuclear translocation IF and downstream NRF1-TFAM (mitochondrial transcription factor A) mRNA qPCR quantify the biogenesis arm.

Mitochondrial ROS in steatotic hepatocytes: MitoSOX Red (mitochondria-targeted superoxide indicator, 5 μM, 10 min, 37°C, flow cytometry 510/580 nm excitation/emission, geometric MFI), MitoTracker Red CMXRos (ΔΨm-dependent), and JC-1 ratiometric ΔΨm assay delineate MOTS-C’s ROS-scavenging versus ΔΨm-protective effects. Electron transport chain complex activity: spectrophotometric assays in isolated mitochondria — Complex I (NADH oxidation, 340 nm, rotenone-sensitive), Complex II (DCPIP reduction, 600 nm), Complex III (cytochrome c reduction, 550 nm), and Complex IV (cytochrome c oxidation, 550 nm) — in palmitate-MOTS-C versus palmitate-vehicle mitochondria establish which ETC steps are protected by MOTS-C treatment.

Hepatic Inflammation Research: Kupffer Cell Activation and NLRP3

NAFLD progression to NASH is driven by hepatic inflammatory activation of Kupffer cells (liver-resident macrophages) and infiltrating bone marrow-derived macrophages. MOTS-C’s AMPK-mediated NF-κB suppression (AMPK phosphorylates IKKβ at an inhibitory site, reducing IκBα Ser-32 phosphorylation and NF-κB p65 nuclear translocation) provides an anti-inflammatory mechanism in Kupffer cell biology. Primary Kupffer cell isolation: Percoll 25/50% two-step gradient centrifugation from collagenase-perfused mouse or rat liver (CD11b+F4/80+ purity ≥85% by flow). LPS (100 ng/mL, 4h) ± MOTS-C (1-10 μM, 30 min pre-treatment) stimulation: NF-κB p65 nuclear western and IF, Luminex TNF-α-IL-1β-IL-6-IL-10-MCP-1 in supernatants at 4h and 24h.

NLRP3 inflammasome in NASH Kupffer cells: two-signal activation protocol (LPS prime 1 μg/mL 3h → ATP 5 mM 30 min or palmitate 0.5 mM 16h as second signal); NLRP3 and ASC western (ASC speck formation by confocal IF); caspase-1 p10 cleavage western (pro-caspase-1 35 kDa → p10/p20 cleavage products); IL-1β (mature p17 versus pro-p31) western and ELISA (R&D DY401). MOTS-C pre-treatment (1-10 μM) reduction of NLRP3 speck formation and IL-1β maturation confirmed by AMPK-dependence (Compound C block) and mitochondrial ROS contribution (MitoSOX, mtROS drives NLRP3 assembly). This Kupffer-NLRP3-IL-1β axis feeds into hepatocyte injury amplification (IL-1β paracrine lipotoxicity) forming the core NASH inflammatory circuit modulated by MOTS-C.

Circulating MOTS-C: Ageing, Exercise, and Hepatic Insulin Resistance Research

Circulating MOTS-C declines with age in both rodents and humans, establishing it as a potential biomarker of metabolic ageing with direct relevance to the age-associated increase in NAFLD and hepatic insulin resistance. In research cohort studies, plasma MOTS-C quantification by validated sandwich ELISA (Phoenix Pharmaceuticals EK-061-95 or equivalent, sensitivity ~0.5 nM) in young (20-35 years) versus middle-aged (45-60 years) versus elderly (>70 years) healthy subjects correlates inversely with HOMA-IR, liver fat by MRI-PDFF, and plasma ALT — establishing the clinical relevance context for exogenous MOTS-C liver research.

Exercise-induced MOTS-C secretion: acute aerobic exercise (60 min cycling at 70% VO₂max, crossover design) elevates plasma MOTS-C ~2-3 fold at 60 min post-exercise in healthy young volunteers (LC-MS/MS quantification, internal standard ¹³C₅-MOTS-C), returning to baseline by 120 min. In rodent exercise models (treadmill, 45 min at 15 m/min, 5×/week, 8 weeks), chronic exercise training increases hepatic MOTS-C (liver homogenate ELISA), AMPK Thr-172 phosphorylation, and mitochondrial content (citrate synthase activity, nmol/mg/min) — establishing the exercise-MOTS-C-AMPK-hepatic metabolism axis that exogenous MOTS-C supplementation research seeks to phenocopy in sedentary/diseased models.

Hepatic Fibrosis: MOTS-C, HSC Biology, and AMPK-TGF-β Crosstalk

In fibrosis-stage NASH, hepatic stellate cell (HSC) activation drives collagen deposition. MOTS-C’s AMPK pathway intersects with HSC biology through AMPK-Smad3 linker phosphorylation (anti-fibrotic mechanism analogous to Thymosin Beta-4’s ILK-Akt-Smad3 crosstalk). LX-2 human HSC line (TGF-β1 10 ng/mL, 24-48h activation) ± MOTS-C (1-10 μM) pre-treatment: α-SMA western and IF; COL1A1 Sircol secreted collagen; Smad2/3 pS465/467 (activation) versus pSer-204 linker (Akt/AMPK-driven inhibition); MMP-2 zymography; TIMP-1/2 ELISA. In the AMLN in vivo model, hepatic collagen quantification by hydroxyproline (Sigma MAK008), Sirius Red area%, and single-cell RNAseq (scRNAseq, 10× Genomics Chromium) of non-parenchymal cell fraction at endpoint — resolving Kupffer subpopulations (KC1 homeostatic C1q+, KC2 inflammatory CCR2+MHC-II+) and HSC activation state (quiescent CYGB+ vs activated ACTA2+COL1A1+) providing the cell-type resolved MOTS-C mechanistic atlas.

Control Conditions and Research Rigour

Rigorous MOTS-C liver research requires: (i) AMPK genetic validation — Ampkα1fl/fl×Ampkα2fl/fl hepatocyte-specific DKO (liver-specific Cre, Alb-Cre) or dominant-negative AMPK adenoviral overexpression to confirm AMPK-dependence of all MOTS-C metabolic endpoints; (ii) folate cycle specificity — AICAR addition (1 mM, positive control for downstream AMPK activation bypassing MOTS-C mechanism) versus MOTS-C, and MTX (dihydrofolate reductase inhibitor) phenocopy confirming upstream folate cycle perturbation; (iii) MOTS-C quantification in samples — plasma and liver homogenate MOTS-C ELISA before treatment to confirm basal levels relevant to the disease model context; (iv) humanin co-treatment controls — humanin (another MDP from 16S rRNA) as the mechanistically related comparator MDP to establish MOTS-C specificity versus broad MDP-class effects; (v) scrambled MOTS-C control — same 16-amino acid composition, randomised sequence (cannot fold or enter cells via the same mechanism); (vi) protein quality — ≥95% HPLC purity, MW 2174 Da MALDI-TOF confirmed, endotoxin ≤1 EU/mg (critical for NAFLD inflammation endpoints); (vii) sex stratification — females show higher baseline AMPK activity and estrogen-mediated MOTS-C sensitivity, requiring sex-stratified cohorts in preclinical models.